Intronix Technologies Corp. Introduces Innovative Myoguide™ System to United States Market
Just cleared by the FDA, revolutionary real-time tool helps with accurately administering targeted injections.
Great things come in small packages, or at least that’s what leading neurologists, physiatrists and clinicians are now discovering with the revolutionary Myoguide Needle EMG Guided Injection System. The breakthrough technology, which has just received 510(k) clearance from the United States Food and Drug Administration, gives practitioners a superior way to deliver targeted injections for myofascial pain, spasticity, fibromyalgia, and even cosmetics.
Small and portable, the handheld package can be easily transported, plus it’s easy to use. Key features include the ability to see and hear EMG signals, display real-time analyzed EMG, and motor point stimulation capability. This provides both the quantitative and qualitative feedback necessary for clinicians to make decisions about treatment, specifically injecting neuromodulators such as Botox©, Xeomin© and Dysport© for the management of pain, movement disorders, spastic muscle management and cosmetic applications. Myoguide incorporates patent-pending technology that’s backed by a 24-month guarantee, and ongoing service and support.
Myoguide will be available directly from our website very soon. This will make it very easy for you to get your own Myoguide unit in the most efficient manner.
We will showcase the system at the 64th American Academy of Neurology’s Annual Meeting, taking place April 21-28, 2012 in New Orleans (http://www.aan.com/go/am12).